國立虎尾科技大學 |

Current Advances in Osteosarcoma = Clinical Perspectives: Past, Present and Future /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Current Advances in Osteosarcoma / edited by Eugenie S. Kleinerman, Richard Gorlick.
其他題名:	Clinical Perspectives: Past, Present and Future /
其他作者:	Gorlick, Richard.
面頁冊數:	XIII, 212 p. 24 illus., 17 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cell Biology. -
電子資源:	https://doi.org/10.1007/978-3-030-43032-0
ISBN:	9783030430320

Current Advances in Osteosarcoma = Clinical Perspectives: Past, Present and Future /
Current Advances in Osteosarcoma Clinical Perspectives: Past, Present and Future /[electronic resource] :edited by Eugenie S. Kleinerman, Richard Gorlick. - 2nd ed. 2020. - XIII, 212 p. 24 illus., 17 illus. in color.online resource. - Advances in Experimental Medicine and Biology,12570065-2598 ;. - Advances in Experimental Medicine and Biology,889.

Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective -- Part 1: Surgical Considerations and Outcomes -- Limb Salvage and Reconstruction Options in Osteosarcoma -- Advances in the functional assessment of patients with sarcoma -- Part II: Novel Therapeutic Approaches Based on Biology -- Radiopharmaceuticals for Treatment of Osteosarcoma -- HER-2 Targeted Therapy in Osteosarcoma -- Aerosolized Chemotherapy for Osteosarcoma -- The Histone Deacetylase inhibitor Entinostat/Syndax 275 in Osteosarcoma -- Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease -- Using liquid biopsy in the treatment of patient with osteosarcoma -- Part III: Novel Immunotherapeutic Approaches -- Genetically modified T-cell therapy for osteosarcoma: into the roaring 2020’s -- Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma -- Natural Killer Cell Immunotherapy for Osteosarcoma -- Nanocapsule delivery of IL-12 -- Discovery of cell surface vimentin (CSV) as a sarcoma target and development of CSV-targeted IL-12 immune therapy -- Part IV: Survivorship and Late Effects -- Editorial Comments on late effects -- Anthracycline-Induced Cardiotoxicity: Causes, mechanisms & prevention -- Exercise and Physical Activity in Patients with Osteosarcoma and Survivors -- Index.

This thoroughly revised second edition complied in 2 books is an up-to-date overview of the current clinical advances in sarcoma and osteosarcoma. The new edition features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, these essential volumes also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists focused in sarcoma.

ISBN: 9783030430320

Standard No.: 10.1007/978-3-030-43032-0doiSubjects--Topical Terms:

593889
Cell Biology.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Current Advances in Osteosarcoma = Clinical Perspectives: Past, Present and Future /
LDR:04152nam a22004095i 4500 001 1020113
003 DE-He213
005 20200630071532.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783030430320 $9 978-3-030-43032-0
024 7 $a 10.1007/978-3-030-43032-0 $2 doi
035 $a 978-3-030-43032-0
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Current Advances in Osteosarcoma $h [electronic resource] : $b Clinical Perspectives: Past, Present and Future / $c edited by Eugenie S. Kleinerman, Richard Gorlick.
250 $a 2nd ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a XIII, 212 p. 24 illus., 17 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 1257
505 0 $a Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective -- Part 1: Surgical Considerations and Outcomes -- Limb Salvage and Reconstruction Options in Osteosarcoma -- Advances in the functional assessment of patients with sarcoma -- Part II: Novel Therapeutic Approaches Based on Biology -- Radiopharmaceuticals for Treatment of Osteosarcoma -- HER-2 Targeted Therapy in Osteosarcoma -- Aerosolized Chemotherapy for Osteosarcoma -- The Histone Deacetylase inhibitor Entinostat/Syndax 275 in Osteosarcoma -- Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease -- Using liquid biopsy in the treatment of patient with osteosarcoma -- Part III: Novel Immunotherapeutic Approaches -- Genetically modified T-cell therapy for osteosarcoma: into the roaring 2020’s -- Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma -- Natural Killer Cell Immunotherapy for Osteosarcoma -- Nanocapsule delivery of IL-12 -- Discovery of cell surface vimentin (CSV) as a sarcoma target and development of CSV-targeted IL-12 immune therapy -- Part IV: Survivorship and Late Effects -- Editorial Comments on late effects -- Anthracycline-Induced Cardiotoxicity: Causes, mechanisms & prevention -- Exercise and Physical Activity in Patients with Osteosarcoma and Survivors -- Index.
520 $a This thoroughly revised second edition complied in 2 books is an up-to-date overview of the current clinical advances in sarcoma and osteosarcoma. The new edition features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, these essential volumes also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists focused in sarcoma.
650 2 4 $a Cell Biology. $3 593889
650 2 4 $a Medical Microbiology. $3 668401
650 1 4 $a Cancer Research. $3 668358
650 0 $a Pediatrics. $3 644839
650 0 $a Cell biology. $3 1253486
650 0 $a Medical microbiology. $3 583124
650 0 $a Cancer research. $3 1253664
700 1 $a Gorlick, Richard. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1315527
700 1 $a Kleinerman, Eugenie S. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1315526
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030430313
776 0 8 $i Printed edition: $z 9783030430337
776 0 8 $i Printed edition: $z 9783030430344
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-3-030-43032-0
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)